BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang H, Zhao X, Yu W. Factors Associated with Recurrence of Hepatocellular Carcinoma in 197 Patients Following Transarterial Chemoembolization: A Retrospective Study from a Single Center. Med Sci Monit 2021;27:e929879. [PMID: 34531359 DOI: 10.12659/MSM.929879] [Reference Citation Analysis]
2 Wang G, Wang Q, Fan X, Ding L, Dong L. The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery. Cancer Manag Res 2019;11:10871-82. [PMID: 31920396 DOI: 10.2147/CMAR.S224583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
3 Sanampudi S, Yu Q, Raissi D. Percutaneous microwave ablation of hepatic lesions near the heart. Transl Gastroenterol Hepatol 2021;6:59. [PMID: 34805581 DOI: 10.21037/tgh-20-314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhang W, Qi S, Zhuo J, Wen S, Fang C. Concordance Study in Hepatectomy Recommendations Between Watson for Oncology and Clinical Practice for Patients with Hepatocellular Carcinoma in China. World J Surg 2020;44:1945-53. [PMID: 32020325 DOI: 10.1007/s00268-020-05401-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ekmen N, Akalin Ç, Akyildiz M. Predictive value of protein induced by absence of vitamin K absence or antagonist II, alpha-fetoprotein and gamma-glutamyltransferase/aspartate aminotransferase ratio for the diagnosis of hepatocellular carcinoma in transplantation candidates. Eur J Gastroenterol Hepatol 2021;32:294-9. [PMID: 32796360 DOI: 10.1097/MEG.0000000000001884] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kim BH, Kim SH, Song IS, Chun GS. The appropriate surgical strategy for T1b gallbladder cancer incidentally diagnosed after a simple cholecystectomy. Ann Hepatobiliary Pancreat Surg 2019;23:327-33. [PMID: 31824997 DOI: 10.14701/ahbps.2019.23.4.327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Sangiovanni A, Triolo M, Iavarone M, Forzenigo LV, Nicolini A, Rossi G, La Mura V, Colombo M, Lampertico P. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. Liver Int 2018;38:1624-34. [DOI: 10.1111/liv.13888] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
8 Brunaldi VO, Brunaldi JE, Vollet-Filho JD, Brunaldi MO, Ardengh JC, Bagnato VS, Dos-Santos JS, Kemp R. Photodynamic therapy of extrahepatic cholangiocarcinoma using digital cholangioscopy. Arq Bras Cir Dig 2020;33:e1490. [PMID: 33206846 DOI: 10.1590/0102-672020190001e1490] [Reference Citation Analysis]
9 Wu Y, Zhou D, Zhang G, Yi F, Feng L. Preoperative Serum Platelet-Lymphocyte Ratio as a Prognostic Factor in Cholangiocarcinoma Patients after Radical Resection: A Retrospective Analysis of 119 Patients. Gastroenterol Res Pract 2019;2019:8506967. [PMID: 30809257 DOI: 10.1155/2019/8506967] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Posadas K, Ankola A, Yang Z, Yee NS. Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study. Biomedicines 2018;6:E46. [PMID: 29673151 DOI: 10.3390/biomedicines6020046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Wang Q, Ma L, Li J, Yuan C, Sun J, Li K, Qin L, Zang C, Zhao Y, Zhao Y, Zhang Y. A Novel Scoring System for Patients with Recurrence of Hepatocellular Carcinoma After Undergoing Minimal Invasive Therapies. Cancer Manag Res 2019;11:10641-9. [PMID: 31908536 DOI: 10.2147/CMAR.S224711] [Reference Citation Analysis]
12 Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu Z, Li Q, Luo M, Liang R, Ye J. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:447. [PMID: 31684985 DOI: 10.1186/s13046-019-1412-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
13 Kwee SA, Tiirikainen M, Sato MM, Acoba JD, Wei R, Jia W, Le Marchand L, Wong LL. Transcriptomics Associates Molecular Features with 18F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma. Cancer Res 2019;79:1696-704. [PMID: 30760520 DOI: 10.1158/0008-5472.CAN-18-3837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
14 Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30. [PMID: 32652308 DOI: 10.1016/j.cgh.2020.06.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
15 Yu P, Wu R, Zhou Z, Zhang X, Wang R, Wang X, Lin S, Wang J, Lv L. rAj-Tspin, a novel recombinant peptide from Apostichopus japonicus, suppresses the proliferation, migration, and invasion of BEL-7402 cells via a mechanism associated with the ITGB1-FAK-AKT pathway. Invest New Drugs 2021;39:377-85. [DOI: 10.1007/s10637-020-01008-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Mirdad RS, Madison Hyer J, Diaz A, Tsilimigras DI, Azap RA, Paro A, Pawlik TM. Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough? J Surg Oncol 2021;123:1568-77. [PMID: 33596330 DOI: 10.1002/jso.26433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kibe Y, Takeda A, Tsurugai Y, Eriguchi T. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies. Acta Oncol 2020;59:888-94. [PMID: 32216593 DOI: 10.1080/0284186X.2020.1741679] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
18 Ransome E, Tong L, Espinosa J, Chou J, Somnay V, Munene G. Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014. J Gastrointest Oncol 2019;10:339-47. [PMID: 31032103 DOI: 10.21037/jgo.2018.12.07] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mendiratta-Lala M, Aslam A, Maturen KE, Westerhoff M, Sun Y, Maurino C, Parikh ND, Sonnenday CJ, Stein EB, Shampain KL, Kaza RK, Cuneo K, Masch W, Do RKG, Lawrence TS, Owen D. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy with Radiologic-Pathologic Explant Correlation in patients with SBRT treated hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02902-3. [PMID: 34644607 DOI: 10.1016/j.ijrobp.2021.10.006] [Reference Citation Analysis]
20 Hodgson A, Almansouri Z, Adeyi O, Fischer SE. Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. J Clin Pathol 2019;72:112-9. [PMID: 30670563 DOI: 10.1136/jclinpath-2018-205596] [Reference Citation Analysis]
21 John S, Moyana T, Shabana W, Walsh C, McInnes MDF. Gallbladder Cancer: Imaging Appearance and Pitfalls in Diagnosis [Formula: see text]. Can Assoc Radiol J 2020;71:448-58. [PMID: 32412302 DOI: 10.1177/0846537120923273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Thomas HR, Feng M. Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma. Curr Hepatology Rep 2021;20:12-22. [DOI: 10.1007/s11901-020-00559-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
23 Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019;28:228-235. [PMID: 30851906 DOI: 10.1016/j.suronc.2019.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
24 Moustafa M, Fasolo E, Bassi D, D'amico FE, Gringeri E, Pawlik TM, Cillo U. The impact of liver resection on survival for locally advanced intrahepatic cholangiocarcinoma tumors: A propensity score analysis. Eur J Surg Oncol 2020;46:632-7. [PMID: 31812289 DOI: 10.1016/j.ejso.2019.11.502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Goel M, Pandrowala S, Parel P, Patkar S. Node positivity in T1b gallbladder cancer: A high volume centre experience. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.03.013] [Reference Citation Analysis]
26 Iancu I, Bartoș A, Cioltean CL, Breazu C, Iancu C, Bartoș D. Role of radio-ablative technique for optimizing the survival of patients with locally advanced pancreatic adenocarcinoma (Review). Exp Ther Med 2021;22:853. [PMID: 34178126 DOI: 10.3892/etm.2021.10285] [Reference Citation Analysis]
27 Chai W, Zhao Q, Kong D, Jiang T. Percutaneous Laser Ablation of Hepatic Tumors Located in the Portacaval Space: Preliminary Results. Lasers Surg Med. 2019;51:866-873. [PMID: 31286541 DOI: 10.1002/lsm.23123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
29 Idrees JJ, Merath K, Gani F, Bagante F, Mehta R, Beal E, Cloyd JM, Pawlik TM. Trends in centralization of surgical care and compliance with National Cancer Center Network guidelines for resected cholangiocarcinoma. HPB 2019;21:981-9. [DOI: 10.1016/j.hpb.2018.11.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
30 Bunyatov T, Zhao A, Kovalenko J, Gurmikov B, Vishnevsky V. Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV. J Gastrointest Oncol 2019;10:815-20. [PMID: 31392064 DOI: 10.21037/jgo.2019.03.05] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
31 Bakopoulos A, Koliakos N, Tsilimigras DI, Schizas D, Moris D, Angelopoulos A, Spanakos S, Spartalis E, Patapis P, Skandalakis P, Troupis T. Management of ruptured liver segment IV hepatocellular carcinoma: is transarterial embolization (TAE) superior to chemoembolization (TACE)?-the jury is still out. Ann Transl Med 2018;6:272. [PMID: 30094258 DOI: 10.21037/atm.2018.06.01] [Reference Citation Analysis]
32 Mouli SK, Goff LW. Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. Curr Treat Options in Oncol 2017;18. [DOI: 10.1007/s11864-017-0509-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Zhang Y, He X, Guo W, Sun L, Guo C, Feng Y. CT‐guided liver beacon transponder implantation. Precision Medical Sciences 2021;10:42-50. [DOI: 10.1002/prm2.12033] [Reference Citation Analysis]
34 Beal EW, Mehta R, Tsilimigras DI, Hyer JM, Paredes AZ, Merath K, Dillhoff ME, Cloyd JM, Ejaz A, Pawlik TM. Travel to a high volume hospital to undergo resection of gallbladder cancer: does it impact quality of care and long-term outcomes? HPB 2020;22:41-9. [DOI: 10.1016/j.hpb.2019.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
35 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
36 Kibe Y, Takeda A, Tsurugai Y, Eriguchi T, Oku Y, Kimura Y, Nakamura N. Feasibility of marker-less stereotactic body radiotherapy for hepatocellular carcinoma. Acta Oncol 2022;61:104-10. [PMID: 34788194 DOI: 10.1080/0284186X.2021.2001566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wada Y, Shimada M, Yamamura K, Toshima T, Banwait JK, Morine Y, Ikemoto T, Saito Y, Baba H, Mori M, Goel A. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma. Hepatology 2021;74:1371-83. [PMID: 33725402 DOI: 10.1002/hep.31803] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
38 Tanaka T, Ozawa H, Nakagawa Y, Hirata A, Fujita S, Sugihara K. Verifying the M1c category of CRC: analysis of the data from a Japanese multi-institutional database. Int J Colorectal Dis 2020;35:125-31. [PMID: 31797096 DOI: 10.1007/s00384-019-03408-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
39 Wang Z, Kang F, Gao Y, Liu Y, Xu X, Ma X, Ma W, Yang W, Wang J. Metformin Promotes 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6-Phosphatase. Mol Imaging Biol 2018;20:388-97. [DOI: 10.1007/s11307-017-1150-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
40 Laschos K, Lampropoulou DI, Aravantinos G, Piperis M, Filippou D, Theodoropoulos G, Gazouli M. Exosomal noncoding RNAs in cholangiocarcinoma: Laboratory noise or hope? World J Gastrointest Surg 2020; 12(10): 407-424 [PMID: 33194090 DOI: 10.4240/wjgs.v12.i10.407] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Li Z, Yu Q, Lu X, Liu Y, Ji B. Efficacy of radiofrequency ablation versus laparoscopic liver resection for hepatocellular carcinoma in China: a comprehensive meta-analysis. Wideochir Inne Tech Maloinwazyjne 2021;16:455-71. [PMID: 34691297 DOI: 10.5114/wiitm.2021.105377] [Reference Citation Analysis]
42 Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
43 O’connor PJ, Pasik SD, van der Bom IM, Bishay V, Radaelli A, Kim E. Feasibility of Yttrium-90 Radioembolization Dose Calculation Utilizing Intra-procedural Open Trajectory Cone Beam CT. Cardiovasc Intervent Radiol 2020;43:295-301. [DOI: 10.1007/s00270-019-02198-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
44 An J, Kim HI, Chang S, Shim JH. Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. PLoS One 2020;15:e0238078. [PMID: 32845895 DOI: 10.1371/journal.pone.0238078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Zheng Y, Zhang X, Lu J, Liu S, Qian Y. Association between socioeconomic status and survival in patients with hepatocellular carcinoma. Cancer Med 2021;10:7347-59. [PMID: 34414679 DOI: 10.1002/cam4.4223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
47 Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, Hickey R, Kulik L, Ganger D, Flamm S, Atassi R, Atassi B, Sato K, Benson AB, Mulcahy MF, Abouchaleh N, Asadi AA, Desai K, Thornburg B, Vouche M, Habib A, Caicedo J, Miller FH, Yaghmai V, Kallini JR, Mouli S, Lewandowski RJ. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2018;68:1429-40. [PMID: 29194711 DOI: 10.1002/hep.29691] [Cited by in Crossref: 111] [Cited by in F6Publishing: 88] [Article Influence: 27.8] [Reference Citation Analysis]
48 Gao X, Huang H, Wang Y, Pan C, Yin S, Zhou L, Zheng S. Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. Front Oncol 2020;10:610513. [PMID: 33680932 DOI: 10.3389/fonc.2020.610513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Köhn N, Maubach J, Warschkow R, Tsai C, Nussbaum DP, Candinas D, Gloor B, Schmied BM, Blazer DG 3rd, Worni M. High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. HPB (Oxford) 2018;20:1073-81. [PMID: 29891423 DOI: 10.1016/j.hpb.2018.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
50 Zhang TQ, Huang ZM, Shen JX, Chen GQ, Shen LJ, Ai F, Gu YK, Yao W, Zhang YY, Guo RP, Chen MS, Huang JH. Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma. Therap Adv Gastroenterol 2019;12:1756284819862966. [PMID: 31489030 DOI: 10.1177/1756284819862966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Spolverato G, Glavas D, Hewitt DB, Brown ZJ, Capelli G, Bergamo F, Rizzato MD, Pawlik TM. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. Expert Opin Pharmacother 2021;:1-9. [PMID: 34964678 DOI: 10.1080/14656566.2021.2020250] [Reference Citation Analysis]
52 Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer 2019;8:281-94. [PMID: 31602371 DOI: 10.1159/000490260] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
53 Liu D, Liu M, Su L, Wang Y, Zhang X, Long H, Kuang M, Xie X, Lin M. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome. J Vasc Interv Radiol 2019;30:1879-86. [PMID: 31669087 DOI: 10.1016/j.jvir.2019.07.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
54 Wang Z, Yu XL, Zhang J, Cheng ZG, Han ZY, Liu FY, Dou JP, Kong Y, Dong XJ, Zhao QX, Yu J, Liang P, Tang WZ. Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study. J Ethnopharmacol 2021;281:114539. [PMID: 34428522 DOI: 10.1016/j.jep.2021.114539] [Reference Citation Analysis]
55 Fruscione M, Pickens RC, Baker EH, Martinie JB, Iannitti DA, Hwang JJ, Vrochides D. Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review. Curr Probl Cancer. 2020;100614. [PMID: 32622478 DOI: 10.1016/j.currproblcancer.2020.100614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
56 Chen S, Shi M, Shen L, Qi H, Wan W, Cao F, Xie L, Wu Y, Chen G, Mo J, Zhu G, Ye D, Zhang Y, Feng Z, Xu L, Fan W. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. Int J Hyperthermia 2020;37:384-91. [PMID: 32323585 DOI: 10.1080/02656736.2020.1752400] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Keane FK, Zhu AX, Hong TS. Radiotherapy for Biliary Tract Cancers. Seminars in Radiation Oncology 2018;28:342-50. [DOI: 10.1016/j.semradonc.2018.06.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
58 Yu JI, Lee SJ, Lee J, Lim HY, Paik SW, Yoo GS, Choi C, Park HC. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Med 2019;8:6986-94. [PMID: 31588679 DOI: 10.1002/cam4.2570] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
59 Ke Q, Chen Y, Huang Q, Lin N, Wang L, Liu J. Does additional resection of a positive microscopic ductal margin benefit patients with perihilar cholangiocarcinoma: A systematic review and meta-analysis. PLoS One 2020;15:e0232590. [PMID: 32379819 DOI: 10.1371/journal.pone.0232590] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Yoo J, Lee JM, Yoon JH, Joo I, Lee DH. Additional Value of Integrated 18F-FDG PET/MRI for Evaluating Biliary Tract Cancer: Comparison with Contrast-Enhanced CT. Korean J Radiol 2021;22:714-24. [PMID: 33660461 DOI: 10.3348/kjr.2020.0689] [Reference Citation Analysis]
61 Leone P, Solimando AG, Fasano R, Argentiero A, Malerba E, Buonavoglia A, Lupo LG, De Re V, Silvestris N, Racanelli V. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines (Basel) 2021;9:532. [PMID: 34065489 DOI: 10.3390/vaccines9050532] [Reference Citation Analysis]
62 Schoenberg SO, Attenberger UI, Solomon SB, Weissleder R. Developing a Roadmap for Interventional Oncology. Oncologist 2018;23:1162-70. [PMID: 29959284 DOI: 10.1634/theoncologist.2017-0654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
63 Wang J, Li Z, Liao Y, Li J, Dong H, Peng H, Xu W, Fan Z, Gao F, Liu C, Liu D, Zhang Y. Prediction of Survival and Analysis of Prognostic Factors for Patients With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Population-Based Study. Front Oncol 2021;11:686972. [PMID: 34336671 DOI: 10.3389/fonc.2021.686972] [Reference Citation Analysis]
64 Sun J, Wang Q, Hong ZX, Li WG, He WP, Zhang T, Zhang AM, Fan YZ, Sun YZ, Zheng L, Duan XZ. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis. Hepatol Int 2020;14:788-97. [PMID: 32886334 DOI: 10.1007/s12072-020-10088-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
65 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
66 Ren AH, Xu H, Yang DW, Zhang N, Ba T, Wang ZC, Yang ZH. Systematic Training of Liver Imaging Reporting and Data System Magnetic Resonance Imaging v2018 can Improve the Diagnosis of Hepatocellular Carcinoma for Different Radiologists. J Clin Transl Hepatol 2021;9:537-44. [PMID: 34447683 DOI: 10.14218/JCTH.2021.00180] [Reference Citation Analysis]
67 Zhao WJ, Zhu GQ, Wu YM, Wang WW, Bai BL. Comparative Effectiveness of Radiofrequency Ablation, Surgical Resection and Transplantation for Early Hepatocellular Carcinoma by Cancer Risk Groups: Results of Propensity Score-Weighted Analysis. Onco Targets Ther 2019;12:10389-400. [PMID: 31819521 DOI: 10.2147/OTT.S224809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Chen H, Jia W. Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes Dis 2020;7:320-7. [PMID: 32884986 DOI: 10.1016/j.gendis.2020.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Zhang F, Lu SX, Hu KS, Gan YH, Chen Y, Ge NL, Yang BW, Zhang L, Chen RX, Ren ZG, Yin X. Albumin-to-alkaline phosphatase ratio as a predictor of tumor recurrence and prognosis in patients with early-stage hepatocellular carcinoma undergoing radiofrequency ablation as initial therapy. Int J Hyperthermia. 2021;38:1-10. [PMID: 33400889 DOI: 10.1080/02656736.2020.1850885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, Ijzermans JNM, Vivarelli M, Zieniewicz K, Olde Damink SWM, Groot Koerkamp B. Surgery for cholangiocarcinoma. Liver Int 2019;39 Suppl 1:143-55. [PMID: 30843343 DOI: 10.1111/liv.14089] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
71 Ogawa H, Nakahira S, Inoue M, Irei T, Hasegawa M, Kato K, Oyama K, Himura H, To T, Maki R, Nishi H, Ohara N, Mikami J, Makari Y, Nakata K, Tsujie M, Fujita J. Our experience of repeat laparoscopic liver resection in patients with recurrent hepatocellular carcinoma. Surg Endosc 2020;34:2113-9. [PMID: 31321532 DOI: 10.1007/s00464-019-06992-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
72 Ostwal V, Swami R, Patkar S, Majumdar S, Goel M, Mehta S, Engineer R, Mandavkar S, Kumar S, Ramaswamy A. Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward. Med Oncol 2018;35:57. [PMID: 29564657 DOI: 10.1007/s12032-018-1115-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Yu Q, Liu C, Pillai A, Ahmed O. Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis. Liver Cancer 2021;10:433-50. [PMID: 34721506 DOI: 10.1159/000516880] [Reference Citation Analysis]
74 Bagante F, Merath K, Squires MH, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg 2018;22:477-85. [DOI: 10.1007/s11605-018-3682-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
75 Schaub SK, Hartvigson PE, Lock MI, Høyer M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS, Apisarnthanarax S. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies. Technol Cancer Res Treat 2018;17:1533033818790217. [PMID: 30068240 DOI: 10.1177/1533033818790217] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
76 Higaki E, Fukaya M, Miyata K, Kawai R, Abe T. Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma. Surg Case Rep 2020;6:138. [PMID: 32548687 DOI: 10.1186/s40792-020-00902-0] [Reference Citation Analysis]
77 Tang A, Singal AG, Mitchell DG, Hecht EM, Fowler KJ, Kulik L, Parikh ND, Kono Y, Sirlin CB. Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2019;17:1228-38. [DOI: 10.1016/j.cgh.2018.10.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
78 Aguado A, Ristagno R, Towbin AJ, Gupta A, Haberle S, Qi Z, Patel MN, Kukreja KU, Tiao GM, Geller JI. Transarterial radioembolization with yttrium‐90 of unresectable primary hepatic malignancy in children. Pediatr Blood Cancer 2019;66:e27510. [DOI: 10.1002/pbc.27510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
79 Wang L, Lin N, Xin F, Zeng Y, Liu J. Comparison of long-term efficacy between endoscopic and percutaneous biliary drainage for resectable extrahepatic cholangiocarcinoma with biliary obstruction: A systematic review and meta-analysis. Saudi J Gastroenterol 2019;25:81-8. [PMID: 30720001 DOI: 10.4103/sjg.SJG_429_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
80 Su TS, Liu QH, Zhu XF, Liang P, Liang SX, Lai L, Zhou Y, Huang Y, Cheng T, Li LQ. Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study. Radiat Oncol 2021;16:79. [PMID: 33882972 DOI: 10.1186/s13014-021-01778-6] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Wang L, Ke Q, Lin N, Zeng Y, Liu J. Does postoperative adjuvant transarterial chemoembolization benefit for all patients with hepatocellular carcinoma combined with microvascular invasion: a meta-analysis. Scandinavian Journal of Gastroenterology 2019;54:528-37. [DOI: 10.1080/00365521.2019.1610794] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
82 Jie T, Guoying F, Gang T, Zhengrong S, Maoping L. Efficacy and Safety of Fusion Imaging in Radiofrequency Ablation of Hepatocellular Carcinoma Compared to Ultrasound: A Meta-Analysis. Front Surg 2021;8:728098. [PMID: 34938766 DOI: 10.3389/fsurg.2021.728098] [Reference Citation Analysis]
83 Wei W, Liu M, Ning S, Wei J, Zhong J, Li J, Cai Z, Zhang L. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma. BMC Cancer 2020;20:6. [PMID: 31898536 DOI: 10.1186/s12885-019-6489-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
84 Kang TW, Kong SY, Kang D, Kang MW, Kim YK, Kim SH, Sinn DH, Kim YA, Choi KS, Lee ES, Woo SM, Back JH, Guallar E, Cho J. Use of Gadoxetic Acid-enhanced Liver MRI and Mortality in More than 30 000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis. Radiology 2020;295:114-24. [PMID: 32013789 DOI: 10.1148/radiol.2020190639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
85 Decraecker M, Toulouse C, Blanc JF. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers (Basel) 2021;13:6310. [PMID: 34944930 DOI: 10.3390/cancers13246310] [Reference Citation Analysis]
86 Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, Maeda S, Tanaka K, Numata K. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology 2019;69:2533-45. [PMID: 30805950 DOI: 10.1002/hep.30591] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
87 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
88 Bagante F, Spolverato G, Gleeson E, Merath K, Ejaz A, Cloyd J, Tsung A, Dillhoff M, Pitt HA, Pawlik TM. Short-Term Outcomes of Patients Undergoing Portal Vein Embolization: an ACS-NSQIP Procedure-Targeted Hepatectomy Analysis. J Gastrointest Surg 2020;24:1571-80. [PMID: 31346961 DOI: 10.1007/s11605-019-04312-y] [Reference Citation Analysis]
89 Wang ML, Ke ZY, Yin S, Liu CH, Huang Q. The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: A meta-analysis and systematic review. Hepatobiliary Pancreat Dis Int 2019;18:110-6. [PMID: 30470543 DOI: 10.1016/j.hbpd.2018.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
90 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584 [PMID: 30310535 DOI: 10.4254/wjh.v10.i9.571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
91 Si M, Yan P, Hao X, Du Z, Tian H, Yang J, Han C, Yang K, Guo T. Efficacy and safety of radiofrequency ablation versus minimally invasive liver surgery for small hepatocellular carcinoma: a systematic review and meta-analysis. Surg Endosc 2019;33:2419-29. [DOI: 10.1007/s00464-019-06784-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
92 Zhou J, Yang W, Zhang S, He X, Lin J, Zhou T, Li Y, Wang G, Chen J. Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma. Cancer Manag Res 2019;11:7159-69. [PMID: 31534368 DOI: 10.2147/CMAR.S217170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
93 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
94 Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 2019;19:795. [PMID: 31409405 DOI: 10.1186/s12885-019-5989-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
95 Liu W, Yang Z, Zou R, Qiu J, Shen J, Liao Y, Wang C, Zhang Y, Wang Y, Yuan Y, Li K, Zuo D, He W, Zheng Y, Li B, Yuan Y. Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study. J Cancer 2019;10:2857-67. [PMID: 31281462 DOI: 10.7150/jca.31246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
96 Yan Y, Lin J, Zhang M, Liu H, Zhou Q, Chen R, Wen K, Wang J, Xiao Z, Mao K. A Novel Staging System to Forecast the Cancer-Specific Survival of Patients With Resected Gallbladder Cancer. Front Oncol 2020;10:1281. [PMID: 32850391 DOI: 10.3389/fonc.2020.01281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Cui R, Wang XH, Ma C, Liu T, Cheng ZG, Han ZY, Liu FY, Yu XL, Yu J, Liang P. Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis. Cancer Manag Res 2019;11:10695-704. [PMID: 31920380 DOI: 10.2147/CMAR.S213581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Chen EY, Cook M, Deig C, Arastu A, Prasad V, Nabavizadeh N, Lopez CD, Kardosh A. Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. JCO Oncol Pract 2021;17:e461-8. [PMID: 33411593 DOI: 10.1200/OP.20.00558] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Sahara K, Tsilimigras DI, Maithel SK, Abbott DE, Poultsides GA, Hatzaras I, Fields RC, Weiss M, Scoggins C, Isom CA, Idrees K, Shen P, Endo I, Pawlik TM; and the US Extrahepatic Biliary Malignancy Consortium. Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium. J Surg Oncol 2020;121:503-10. [PMID: 31907941 DOI: 10.1002/jso.25825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
100 Xu Z, Xie H, Zhou L, Chen X, Zheng S. The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2019;2019:8619096. [PMID: 31534899 DOI: 10.1155/2019/8619096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
101 Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control 2018;25:1073274817744621. [PMID: 29327594 DOI: 10.1177/1073274817744621] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
102 Xiang JX, Zhang XF, Weber SM, Poultsides G, Fields RC, Hatzaras I, Weiss M, Scoggins C, Idrees K, Shen P, Maithel SK, Pawlik TM. Identification of patients who may benefit the most from adjuvant chemotherapy following resection of incidental gallbladder carcinoma. J Surg Oncol 2021;123:978-85. [PMID: 33497466 DOI: 10.1002/jso.26389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
103 Gu X, Li H, Sha L, Zhao W. A prognostic model composed of four long noncoding RNAs predicts the overall survival of Asian patients with hepatocellular carcinoma. Cancer Med 2020;9:5719-30. [PMID: 32946170 DOI: 10.1002/cam4.3275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
104 Toyonaga H, Hayashi T, Ueki H, Chikugo K, Ishii T, Nasuno H, Kin T, Takahashi K, Takada M, Ambo Y, Shinohara T, Yamazaki H, Katanuma A. An intact boundary between the tumor and inner hypoechoic layer discriminates T1 lesions among sessile elevated gallbladder cancers. J Hepatobiliary Pancreat Sci 2021. [PMID: 33826798 DOI: 10.1002/jhbp.961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Wu L, Tang Q, Yin X, Yan D, Tang M, Xin J, Pan Q, Ma C, Yan S. The Therapeutic Potential of Adipose Tissue-Derived Mesenchymal Stem Cells to Enhance Radiotherapy Effects on Hepatocellular Carcinoma. Front Cell Dev Biol 2019;7:267. [PMID: 31781559 DOI: 10.3389/fcell.2019.00267] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
106 Liu S, Zhong Z, Yi W, Yu Z, Zhang Z, Xia G, Jiang B, Song Y, Peng C. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy Combined with Radical Surgery and Capecitabine on Stage III Gallbladder Cancer. Can J Gastroenterol Hepatol 2021;2021:4006786. [PMID: 34660468 DOI: 10.1155/2021/4006786] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Chua D, Low A, Koh Y, Goh B, Cheow PC, Kam JH, Teo JY, Tan EK, Chung A, Ooi LL, Chan CY, Lee SY. A retrospective review of correlative radiological assessment and surgical exploration for hilar cholangiocarcinoma. Ann Hepatobiliary Pancreat Surg 2018;22:216-22. [PMID: 30215043 DOI: 10.14701/ahbps.2018.22.3.216] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Wu J, Ding W, Wang Y, Liu S, Zhang X, Yang Q, Cai W, Yu X, Liu F, Kong D, Zhong H, Yu J, Liang P. Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation. International Journal of Hyperthermia 2022;39:595-604. [DOI: 10.1080/02656736.2022.2062463] [Reference Citation Analysis]
109 Floudas CS, Brar G, Greten TF. Immunotherapy: Current Status and Future Perspectives. Dig Dis Sci 2019;64:1030-40. [DOI: 10.1007/s10620-019-05516-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
110 Ye J, Wu Y, Li M, Gong X, Zhong B. Keratin 8 Mutations Were Associated With Susceptibility to Chronic Hepatitis B and Related Progression. J Infect Dis 2020;221:464-73. [PMID: 31515557 DOI: 10.1093/infdis/jiz467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Meng LM, Zhiyan LM, Yuejuan GM, Jiangke TM, Min CM, Jinghui DM. Safety and Efficacy of Percutaneous Radiofrequency Ablation Combined with Percutaneous Ethanol Injection for Hepatocellular Carcinoma in High-risk Locations. Advanced Ultrasound in Diagnosis and Therapy 2018;2:1. [DOI: 10.37015/audt.2018.180004] [Reference Citation Analysis]
112 Gilabert M, Raoul JL. Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. J Hepatocell Carcinoma 2018;5:91-8. [PMID: 30464931 DOI: 10.2147/JHC.S157413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
113 Li J, Moustafa M, Linecker M, Lurje G, Capobianco I, Baumgart J, Ratti F, Rauchfuss F, Balci D, Fernandes E, Montalti R, Robles-Campos R, Bjornsson B, Topp SA, Fronek J, Liu C, Wahba R, Bruns C, Brunner SM, Schlitt HJ, Heumann A, Stüben BO, Izbicki JR, Bednarsch J, Gringeri E, Fasolo E, Rolinger J, Kristek J, Hernandez-Alejandro R, Schnitzbauer A, Nuessler N, Schön MR, Voskanyan S, Petrou AS, Hahn O, Soejima Y, Vicente E, Castro-Benitez C, Adam R, Tomassini F, Troisi RI, Kantas A, Oldhafer KJ, Ardiles V, de Santibanes E, Malago M, Clavien PA, Vivarelli M, Settmacher U, Aldrighetti L, Neumann U, Petrowsky H, Cillo U, Lang H, Nadalin S. ALPPS for Locally Advanced Intrahepatic Cholangiocarcinoma: Did Aggressive Surgery Lead to the Oncological Benefit? An International Multi-center Study. Ann Surg Oncol 2020;27:1372-84. [PMID: 32002719 DOI: 10.1245/s10434-019-08192-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
114 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
115 Birgin E, Kaslow SR, Hetjens S, Correa-Gallego C, Rahbari NN. Minimally Invasive versus Open Liver Resection for Stage I/II Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4800. [PMID: 34638285 DOI: 10.3390/cancers13194800] [Reference Citation Analysis]
116 Le N, Fillinger J, Szanyi S, Wichmann B, Nagy Z, Ivády G, Burai M, Tarpay Á, Pozsár J, Pap Á, Molnár B, Csuka O, Bak M, Tulassay Z, Szmola R. Analysis of microRNA expression in brush cytology specimens improves the diagnosis of pancreatobiliary cancer. Pancreatology 2019;19:873-9. [DOI: 10.1016/j.pan.2019.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
117 Dong Y, Wang G, Zhang J, Zhang S, Chen X, Guo Q, Qu F, Shou F. Robotic laser position versus freehand in CT-guided percutaneous microwave ablation for single hepatocellular carcinoma (diameter < 3 cm): a preliminary study. Int J Hyperthermia 2022;39:725-32. [PMID: 35584811 DOI: 10.1080/02656736.2022.2072526] [Reference Citation Analysis]
118 Wang L, Lin ZG, Ke Q, Lou JY, Zheng SG, Bi XY, Wang JM, Guo W, Li FY, Wang J, Zheng YM, Li JD, Cheng S, Zhou WP, Zeng YY. Adjuvant transarterial chemoembolization following radical resection for intrahepatic cholangiocarcinoma: A multi-center retrospective study. J Cancer 2020;11:4115-22. [PMID: 32368294 DOI: 10.7150/jca.40358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Tang Z, Tang Y, Liu T, Liu R, Xie S, Xie D, Yang J, Tang Y. Clinical Study on the Efficacy of Laparoscopic Hepatectomy and Its Influence on the Expression of Serum VEGF, FGF, and Immune Function. Evid Based Complement Alternat Med 2021;2021:4432022. [PMID: 34650612 DOI: 10.1155/2021/4432022] [Reference Citation Analysis]
120 Fumarola EM, Ierardi AM, Biondetti P, Savoldi AP, Grillo P, Gorga G, Coppola A, Carrafiello G. Follow-up of percutaneous microwave (MW) ablation of hepatic lesion: predictive value of CT at 24-h compared with CT at 1 month. Med Oncol 2020;37:41. [PMID: 32266568 DOI: 10.1007/s12032-020-01364-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Schreuder AM, Engelsman AF, van Roessel S, Verheij J, Besselink MG, van Gulik TM, Busch OR. Treatment of mid-bile duct carcinoma: Local resection or pancreatoduodenectomy? European Journal of Surgical Oncology 2019;45:2180-7. [DOI: 10.1016/j.ejso.2019.06.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Sarwar A, Kudla A, Weinstein JL, Ali A, Malik R, Bullock A, Khwaja KO, Curry M, Faintuch S, Ahmed M. Yttrium-90 radioembolization using MIRD dosimetry with resin microspheres. Eur Radiol 2021;31:1316-24. [PMID: 32901301 DOI: 10.1007/s00330-020-07231-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Kouri BE. Interventional Oncology: Optimizing Transarterial Therapies for the Treatment of Hepatic Malignancy. Techniques in Vascular and Interventional Radiology 2018;21:205-22. [DOI: 10.1053/j.tvir.2018.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
124 Berardi R, Mocchegiani F, Rinaldi S, Fiordoliva I, Rovinelli F, Caramanti M, Federici A, Burattini M, Morgese F, Torniai M, Marcantognini G, Vivarelli M. Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study. Oncol Ther 2020;8:115-24. [PMID: 32700076 DOI: 10.1007/s40487-020-00112-6] [Reference Citation Analysis]
125 Su TS, Li LQ, Liang SX, Xiang BD, Li JX, Ye JZ, Li LQ. A Prospective Study of Liver Regeneration After Radiotherapy Based on a New (Su'S) Target Area Delineation. Front Oncol 2021;11:680303. [PMID: 34513671 DOI: 10.3389/fonc.2021.680303] [Reference Citation Analysis]
126 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
127 Camacho JC, Petre EN, Sofocleous CT. Thermal Ablation of Metastatic Colon Cancer to the Liver. Semin Intervent Radiol 2019;36:310-8. [PMID: 31680722 DOI: 10.1055/s-0039-1698754] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
128 Sinagra E, Garritano S, Iacopinelli SM, Messina M, Raimondo D, Rossi F, Spada M, Martorana G, Spampinato MG. Minimally invasive surgical approach for radicalization of incidental post-cholecystectomy gallbladder carcinoma: safety, feasibility and outcomes. Minim Invasive Ther Allied Technol 2018;27:217-20. [PMID: 29214888 DOI: 10.1080/13645706.2017.1410489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
129 Aslakson RA, Chandrashekaran SV, Rickerson E, Fahy BN, Johnston FM, Miller JA, Conca-Cheng A, Wang S, Morris AM, Lorenz K, Temel JS, Smith TJ. A Multicenter, Randomized Controlled Trial of Perioperative Palliative Care Surrounding Cancer Surgery for Patients and Their Family Members (PERIOP-PC). J Palliat Med 2019;22:44-57. [PMID: 31486730 DOI: 10.1089/jpm.2019.0130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
130 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
131 Wang J, Liu J, Chang Q, Yang B, Li S, Gu C. The association between preoperative serum interleukin-6 levels and postoperative prognosis in patients with T2 gallbladder cancer. J Surg Oncol 2018;117:1672-8. [PMID: 29723410 DOI: 10.1002/jso.25085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
132 de Geus SW, Woods AP, Papageorge MV, Zheng J, Ng SC, McAneny D, Sachs TE, Tseng JF. Combined Hepatopancreaticobiliary Volume and Hepatectomy Outcomes in Hepatocellular Carcinoma Patients at Low-Volume Liver Centers. J Am Coll Surg 2021;232:864-71. [PMID: 33640522 DOI: 10.1016/j.jamcollsurg.2021.01.017] [Reference Citation Analysis]
133 Jin H, Wang H, Li G, Hou Q, Wu W, Liu F. Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma. J Int Med Res 2020;48:300060520961260. [PMID: 33044114 DOI: 10.1177/0300060520961260] [Reference Citation Analysis]
134 Du Y, Ma X, Wang D, Wang Y, Zhang T, Bai L, Liu Y, Chen S. Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma. J Gastrointest Oncol 2021;12:2361-76. [PMID: 34790398 DOI: 10.21037/jgo-21-468] [Reference Citation Analysis]
135 Wei F, Huang Q, Zhou Y, Luo L, Zeng Y. Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study. World J Surg Oncol 2021;19:175. [PMID: 34127007 DOI: 10.1186/s12957-021-02277-4] [Reference Citation Analysis]
136 Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(10): 693-708 [PMID: 33200010 DOI: 10.4254/wjh.v12.i10.693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
137 Li D, Cheng Z, Chen G, Liu F, Wu W, Yu J, Gu Y, Liu F, Ren C, Liang P. A multimodality imaging-compatible insertion robot with a respiratory motion calibration module designed for ablation of liver tumors: a preclinical study. International Journal of Hyperthermia 2018;34:1194-201. [DOI: 10.1080/02656736.2018.1456680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Zhu Y, Gu L, Chen T, Zheng G, Ye C, Jia W. Factors influencing early recurrence of hepatocellular carcinoma after curative resection. J Int Med Res 2020;48:300060520945552. [PMID: 33106072 DOI: 10.1177/0300060520945552] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Su TS, Liang P, Zhou Y, Huang Y, Cheng T, Qu S, Chen L, Xiang BD, Zhao C, Huang DJ, Liang SX, Li LQ. Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. Front Oncol 2020;10:347. [PMID: 32266136 DOI: 10.3389/fonc.2020.00347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
140 Lee W, Jeong CY, Kim YH, Roh YH, Yoon MH, Seo HI, Park JI, Jung BH, Shin DH, Choi YI, Ryu JH, Yang KH, Choi CS, Park YH, Nah YW, Hong SC. Validation of the prognostic performance in various nodal staging systems for gallbladder cancer: results of a multicenter study. Langenbecks Arch Surg 2019;404:581-8. [PMID: 31414179 DOI: 10.1007/s00423-019-01807-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
141 Xiao Z, Yan Y, Zhou Q, Liu H, Huang P, Zhou Q, Lai C, Zhang J, Wang J, Mao K. Development and external validation of prognostic nomograms in hepatocellular carcinoma patients: a population based study. Cancer Manag Res 2019;11:2691-708. [PMID: 31118768 DOI: 10.2147/CMAR.S191287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
142 Yin Y, Wu S, Zhao X, Zou L, Luo A, Deng F, Min M, Jiang L, Liu H, Wu X. Whole exome sequencing study of a Chinese concurrent cancer family. Oncol Lett 2019;18:2619-27. [PMID: 31452746 DOI: 10.3892/ol.2019.10573] [Reference Citation Analysis]
143 Yang Y, Tu Z, Cai H, Hu B, Ye C, Tu J. A predictive nomogram for lymph node metastasis of incidental gallbladder cancer: a SEER population-based study. BMC Cancer 2020;20:828. [PMID: 32867722 DOI: 10.1186/s12885-020-07341-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
144 D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G. Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Rev Clin Pharmacol 2020;13:623-9. [PMID: 32394749 DOI: 10.1080/17512433.2020.1767591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
145 Mao K, Yan Y, Zhang J, Wang J, Wang R, Ling X, Liu Y, Lau WY, Jiang S, Liu J, Xiao Z. The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: A propensity score matching study. Cancer Med 2018;7:4475-84. [PMID: 30117307 DOI: 10.1002/cam4.1738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
146 Pang J, Hao G, Chen Y. Clinical effects and prognosis of stereotactic body radiotherapy combined with transarterial chemoembolization for massive hepatocellular carcinoma. Prec Radiat Oncol 2021;5:12-7. [DOI: 10.1002/pro6.1111] [Reference Citation Analysis]
147 Mohammadi H, Abuodeh Y, Jin W, Frakes J, Friedman M, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Hoffe S. Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma. J Gastrointest Oncol. 2018;9:840-846. [PMID: 30505583 DOI: 10.21037/jgo.2018.05.14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
148 Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. World J Hepatol 2022; 14(5): 885-895 [DOI: 10.4254/wjh.v14.i5.885] [Reference Citation Analysis]
149 Yuan C, Wang Z, Gu D, Tian J, Zhao P, Wei J, Yang X, Hao X, Dong D, He N, Sun Y, Gao W, Feng J. Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram. Cancer Imaging. 2019;19:21. [PMID: 31027510 DOI: 10.1186/s40644-019-0207-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
150 Choi SH, Seong J. Strategic Application of Radiotherapy for Hepatocellular Carcinoma. Clin Mol Hepatol. 2018; Epub ahead of print. [PMID: 29439305 DOI: 10.3350/cmh.2017.0073] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
151 Yan B, Su BB, Bai DS, Qian JJ, Zhang C, Jin SJ, Jiang GQ. A practical nomogram and risk stratification system predicting the cancer-specific survival for patients with early hepatocellular carcinoma. Cancer Med 2021;10:496-506. [PMID: 33280269 DOI: 10.1002/cam4.3613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 Yang H, Yang Y, Dou J, Cui R, Cheng Z, Han Z, Liu F, Yu X, Zhou X, Yu J, Liang P. Cholecystectomy is associated with higher risk of recurrence after microwave ablation of hepatocellular carcinoma: a propensity score matching analysis. Cancer Biol Med 2020;17:478-91. [PMID: 32587783 DOI: 10.20892/j.issn.2095-3941.2019.0246] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
153 Fasano R, Shadbad MA, Brunetti O, Argentiero A, Calabrese A, Nardulli P, Calbi R, Baradaran B, Silvestris N. Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life (Basel) 2021;11:1355. [PMID: 34947886 DOI: 10.3390/life11121355] [Reference Citation Analysis]
154 Akce M, Zakka K, Penley M, Jiang R, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF. Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. J Surg Oncol 2019. [PMID: 31782161 DOI: 10.1002/jso.25781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
155 Lee EJ, Chung HW, Jo JH, So Y. Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. Nucl Med Mol Imaging 2019;53:367-73. [PMID: 31867071 DOI: 10.1007/s13139-019-00615-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
156 Lin N, Li J, Ke Q, Wang L, Cao Y, Liu J. Clinical Significance of C-Reactive Protein to Albumin Ratio in Patients with Hepatocellular Carcinoma: A Meta-Analysis.Dis Markers. 2020;2020:4867974. [PMID: 32963635 DOI: 10.1155/2020/4867974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Kamarajah SK, Bundred JR, Littler P, Reeves H, Manas DM, White SA. Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. HPB (Oxford) 2021;23:495-505. [PMID: 33309569 DOI: 10.1016/j.hpb.2020.10.031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Lu JW, Sun Y, Lin LI, Liu D, Gong Z. Exacerbation of Liver Tumor Metastasis in twist1a+/xmrk+ Double Transgenic Zebrafish following Lipopolysaccharide or Dextran Sulphate Sodium Exposure. Pharmaceuticals (Basel) 2021;14:867. [PMID: 34577566 DOI: 10.3390/ph14090867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Chen SH, Xu LY, Wu YP, Ke ZB, Huang P, Lin F, Li XD, Xue XY, Wei Y, Zheng QS, Xu N. Tumor volume: a new prognostic factor of oncological outcome of localized clear cell renal cell carcinoma. BMC Cancer 2021;21:79. [PMID: 33468079 DOI: 10.1186/s12885-021-07795-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Samuel S, Mukherjee S, Ammannagari N, Pokuri VK, Kuvshinoff B, Groman A, LeVea CM, Iyer R. Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. PLoS One 2018;13:e0198809. [PMID: 29889907 DOI: 10.1371/journal.pone.0198809] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
161 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
162 De Lorenzo S, Tovoli F, Barbera MA, Garuti F, Palloni A, Frega G, Garajovà I, Rizzo A, Trevisani F, Brandi G. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. Sci Rep 2018;8:9997. [PMID: 29968763 DOI: 10.1038/s41598-018-28337-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
163 Liu W, Zheng Y, Zou R, Shen J, He W, Yang Z, Zhang Y, Li B, Yuan Y. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer 2018;18:1186. [PMID: 30497418 DOI: 10.1186/s12885-018-5069-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
164 Puza CJ, Wang Q, Kim CY. Evaluation of the Heat Sink Effect After Transarterial Embolization When Performed in Combination with Thermal Ablation of the Liver in a Rabbit Model. Cardiovasc Intervent Radiol 2018;41:1773-8. [PMID: 30039505 DOI: 10.1007/s00270-018-2034-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
165 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6:387-396. [PMID: 29312973 DOI: 10.21037/hbsn.2017.11.01] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
166 Navin PJ, Venkatesh SK. Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. J Clin Transl Hepatol 2019;7:72-85. [PMID: 30944823 DOI: 10.14218/JCTH.2018.00032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
167 Li J, Moustafa M, Meiners J, Stüben O, Izbicki J, Heumann A. ASO Author Reflections: Optimizing the Oncological Outcome for Locally Advanced Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2020;27:1385-6. [PMID: 32124123 DOI: 10.1245/s10434-020-08274-3] [Reference Citation Analysis]
168 Wu B, Shen Y, Chen X, Wang X, Zhong Z. Effect of lymphadenectomy on the prognosis for N0 gallbladder carcinoma patients: A study based on SEER database. Cancer Med 2021;10:7136-43. [PMID: 34519168 DOI: 10.1002/cam4.4250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Bagante F, Gani F, Beal EW, Merath K, Chen Q, Dillhoff M, Cloyd J, Pawlik TM. Prognosis and Adherence with the National Comprehensive Cancer Network Guidelines of Patients with Biliary Tract Cancers: an Analysis of the National Cancer Database. J Gastrointest Surg 2019;23:518-28. [DOI: 10.1007/s11605-018-3912-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
170 Zhang T, Zhang S, Jin C, Lin Z, Deng T, Xie X, Deng L, Li X, Ma J, Ding X, Liu Y, Shan Y, Yu Z, Wang Y, Chen G, Li J. A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients With Cholangiocarcinoma. Front Cell Infect Microbiol 2021;11:751795. [PMID: 34888258 DOI: 10.3389/fcimb.2021.751795] [Reference Citation Analysis]
171 Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Mitchell DG, Cerny M, Elsayes KM, Santillan C, Kamaya A, Kono Y, Sirlin CB, Tang A. LI-RADS 2017: An update. J Magn Reson Imaging 2018;47:1459-74. [PMID: 29626376 DOI: 10.1002/jmri.26027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
172 Zolotovskaia MA, Sorokin MI, Petrov IV, Poddubskaya EV, Moiseev AA, Sekacheva MI, Borisov NM, Tkachev VS, Garazha AV, Kaprin AD, Shegay PV, Giese A, Kim E, Roumiantsev SA, Buzdin AA. Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. Int J Mol Sci 2020;21:E1580. [PMID: 32111026 DOI: 10.3390/ijms21051580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
173 Chen S, Wu Y, Qi H, Shen L, Ma W, Cao F, Diao Y, Wang T, Ou S, Fan W. Single-nodule hepatitis B virus-associated hepatocellular carcinoma smaller than 3 cm: two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy. Int J Hyperthermia 2021;38:120-9. [PMID: 33541160 DOI: 10.1080/02656736.2021.1876930] [Reference Citation Analysis]
174 Beal EW, Cloyd JM, Pawlik TM. Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. J Clin Med 2020;10:E104. [PMID: 33396821 DOI: 10.3390/jcm10010104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
175 Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;75:1289-99. [PMID: 34778999 DOI: 10.1002/hep.32240] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
176 Kamarajah SK, Al-Rawashdeh W, White SA, Abu Hilal M, Salti GI, Dahdaleh FS. Adjuvant radiotherapy improves long-term survival after resection for gallbladder cancer A population-based cohort study. Eur J Surg Oncol 2021:S0748-7983(21)00724-1. [PMID: 34518052 DOI: 10.1016/j.ejso.2021.09.002] [Reference Citation Analysis]
177 Lin YL. Proton beam therapy in apneic oxygenation treatment of an unresectable hepatocellular carcinoma: A case report and review of literature. World J Hepatol 2018; 10(10): 772-779 [PMID: 30386470 DOI: 10.4254/wjh.v10.i10.772] [Reference Citation Analysis]
178 Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma? Dig Dis Sci 2019;64:918-27. [PMID: 30838478 DOI: 10.1007/s10620-019-05517-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
179 Mahmud N, John B, Taddei TH, Goldberg DS. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality. Clin Transplant. 2019;33:e13634. [PMID: 31177570 DOI: 10.1111/ctr.13634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]